drugset
drugset / Trial / NCT00329121

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ

NCT00329121 ↗

Phase 2 Completed 24 enrolled Peplin
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the topical application of PEP005 is safe and effective for the treatment of cutaneous squamous cell carcinoma in situ (SCCIS, Bowen's disease).

Timeline

Start
2006-05
Primary completion
2006-12
Completion
2006-12

Publications

  • Results Rosen R, Freeman M, Siller G, Zibert JR, Katsamas J, Knudsen KM, Spelman L. Ingenol mebutate 0.05% gel reduces cancer cells in squamous cell carcinoma in situ and shows marginal effect in seborrheic keratosis. JDDG J German Soc Dermatol 2013; 11(Suppl. 7): 22

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule 0.05 % Topical

Indications

skin squamous cell carcinoma